Search for a doctor

Tufia C. Haddad, M.D.

  1. Oncologist
Request an Appointment

Publications

  1. Haemmerle R, Paludo J, Haddad TC, Pritchett JC. The Growing Role of Digital Health Tools in the Care of Patients with Cancer: Current Use, Future Opportunities, and Barriers to Effective Implementation. Curr Oncol Rep. 2024 Apr 23 [Epub ahead of print]
    View PubMed
  2. Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 Feb 16; 30 (4):729-740
    View PubMed
  3. Lynce F, Stevens LE, Li Z, Brock JE, Gulvady A, Huang Y, Nakhlis F, Patel A, Force JM, Haddad TC, Ueno N, Stearns V, Wolff AC, Clark AS, Bellon JR, Richardson ET, Balko JM, Krop IE, Winer EP, Lange P, Hwang ES, King TA, Tolaney SM, Thompson A, Gupta GP, Mittendorf EA, Regan MM, Overmoyer B, Polyak K. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 Jan 31; 26 (1):20
    View PubMed
  4. Pritchett JC, Paludo JC, Borah BJ, Haddad TC. Remote patient monitoring to transform management of febrile neutropenia in cancer patients. NEJM Catalyst Innovations in Care Delivery. 2024; 5 (4)
  5. Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko JM, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon KA, Goetz M, Haddad TC, Iwata H, Jassem J, Lee SC, Linderholm B, Los M, Mamounas EP, Miller KD, Morris PG, Munzone E, Gal-Yam EN, Ring A, Shepherd L, Singer C, Thomssen C, Tseng LM, Valagussa P, Winer EP, Wolff AC, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck AC, DeMichele A, Gnant M, PALLAS Groups and Investigators. Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. J Clin Oncol. 2023 Nov 20; 41 (33):5118-5130 Epub 2023 Aug 09
    View PubMed
  6. Young NP, Ridgeway JL, Haddad TC, Harper SB, Philpot LM, Christopherson LA, McColley SM, Phillips SA, Brown JK, Zimmerman KS, Ebbert JO. Feasibility and Usability of a Mobile App-Based Interactive Care Plan for Migraine in a Community Neurology Practice: Development and Pilot Implementation Study. JMIR Form Res. 2023 Oct 5; 7:e48372 Epub 2023 Oct 05
    View PubMed
  7. Cathcart-Rake EJ, Tevaarwerk AJ, Haddad TC, D'Andre SD, Ruddy KJ. Advances in the care of breast cancer survivors. BMJ. 2023 Sep 18; 382:e071565 Epub 2023 Sept 18
    View PubMed
  8. Pritchett JC, Borah BJ, Dholakia R, Moriarty JP, Ahn HH, Huang M, Khera N, Wilshusen L, Dronca RS, Ticku J, Leppin AL, Tilburt JC, Paludo J, Haddad TC. Patient- and Provider-Level Factors Associated With Telehealth Utilization Across a Multisite, Multiregional Cancer Practice From 2019 to 2021. JCO Oncol Pract. 2023 Sep; 19 (9):750-758 Epub 2023 June 19
    View PubMed
  9. Sehrawat O, Noseworthy PA, Siontis KC, Haddad TC, Halamka JD, Liu H. Data-Driven and Technology-Enabled Trial Innovations Toward Decentralization of Clinical Trials: Opportunities and Considerations. Mayo Clin Proc. 2023 Sep; 98 (9):1404-1421
    View PubMed
  10. Haddad TC, Maita KC, Inselman JW, Avila FR, Torres-Guzman RA, Coffey JD, Christopherson LA, Leuenberger AM, Bell SJ, Pahl DF, Garcia JP, Manka L, Forte AJ, Maniaci MJ. Patient Satisfaction With a Multisite, Multiregional Remote Patient Monitoring Program for Acute and Chronic Condition Management: Survey-Based Analysis. J Med Internet Res. 2023 Jul 27; 25:e44528 Epub 2023 July 27
    View PubMed
  11. Joshi U, Budhathoki P, Gaire S, Yadav SK, Shah A, Adhikari A, Choong G, Couzi R, Giridhar KV, Leon-Ferre RA, Boughey JC, Hieken TJ, Mutter R, Ruddy KJ, Haddad TC, Goetz MP, Couch FJ, Yadav S. Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2023 Jul; 200 (2):217-224 Epub 2023 May 21
    View PubMed
  12. Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O'Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. JAMA Oncol. 2023 Jun 1; 9 (6):815-824
    View PubMed
  13. Vijayakumar J, Haddad T, Gupta K, Sauers J, Yee D. An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. Invest New Drugs. 2023 Feb; 41 (1):70-75 Epub 2022 Nov 28
    View PubMed
  14. Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, Scott CG, Thompson CA, Cerhan JR, Haddad TC, Goetz MP, Herrmann J, Villarraga HR. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010. JAMA Netw Open. 2023 Feb 1; 6 (2):e2254669 Epub 2023 Feb 01
    View PubMed
  15. Haddad TC, Coffey JD, Deng Y, Glasgow AE, Christopherson LA, Sangaralingham LR, Bell SJ, Shah VP, Pritchett JC, Orenstein R, Speicher LL, Maniaci MJ, Ganesh R, Borah BJ. Impact of a High-Risk, Ambulatory COVID-19 Remote Patient Monitoring Program on Utilization, Cost, and Mortality. Mayo Clin Proc. 2022 Dec; 97 (12):2215-2225 Epub 2022 Sept 06
    View PubMed
  16. Choong GM, Liddell S, Ferre RAL, O'Sullivan CC, Ruddy KJ, Haddad TC, Hobday TJ, Peethambaram PP, Liu MC, Goetz MP, Giridhar KV. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. Breast Cancer Res Treat. 2022 Nov; 196(1):229-237. Epub 2022 Aug 31.
    View PubMed
  17. Koehler L, Day A, Hunter D, Blaes A, Haddad T, Shanley R. Five-Year Cumulative Incidence of Axillary Web Syndrome and Comparison in Upper Extremity Movement, Function, Pain, and Lymphedema in Survivors of Breast Cancer With and Without Axillary Web Syndrome. Arch Phys Med Rehabil. 2022 Sep; 103 (9):1798-1806 Epub 2022 Apr 06
    View PubMed
  18. Demaerschalk BM, Pines A, Butterfield R, Haglin JM, Haddad TC, Yiannias J, Colby CE, TerKonda SP, Ommen SR, Bushman MS, Lokken TG, Blegen RN, Hoff MD, Coffey JD, Anthony GS, Zhang N, Diagnostic Accuracy of Telemedicine Utilized at Mayo Clinic Alix School of Medicine Study Group Investigators. Assessment of Clinician Diagnostic Concordance With Video Telemedicine in the Integrated Multispecialty Practice at Mayo Clinic During the Beginning of COVID-19 Pandemic From March to June 2020. JAMA Netw Open. 2022 Sep 01; 5(9):e2229958.
    View PubMed
  19. Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, Tutt A, Abramson V, Dean E, Haddad TC, Wesolowski R, Ferrer-Playan J, Goddemeier T, Grombacher T, Dong J, Fleuranceau-Morel P, Diaz-Padilla I, Plummer R. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. NPJ Breast Cancer. 2022 Apr 7; 8 (1):45 Epub 2022 Apr 07
    View PubMed
  20. Shreve JT, Khanani SA, Haddad TC. Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-10
    View PubMed
  21. Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele A. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 2022 Feb 10; 40 (5):449-458 Epub 2022 Jan 07
    View PubMed
  22. Stan DL, Inselman JW, Ridgeway JL, Johnson KN, Christopherson LA, McColley SM, Brown JK, Phillips SA, Allen SV, Hazelton JK, Ruddy KJ, Haddad TC. Pilot implementation to assess the feasibility and care team impact of an app-based interactive care plan to remotely monitor breast cancer survivors. J Cancer Surviv. 2022 Feb; 16(1):13-23. Epub 2022 Feb 02.
    View PubMed
  23. Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernandez de Aranguiz B, Haddad TC, Perello A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL, PALLAS groups and investigators. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022 Jan 20; 40 (3):282-293 Epub 2021 Dec 07
    View PubMed
  24. Choudhery S, Gomez-Cardona D, Favazza CP, Hoskin TL, Haddad TC, Goetz MP, Boughey JC. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Acad Radiol. 2022 Jan; 29 Suppl 1 (Suppl 1):S145-S154 Epub 2020 Nov 05
    View PubMed
  25. Coffey JD, Christopherson LA, Williams RD, Gathje SR, Bell SJ, Pahl DF, Manka L, Blegen RN, Maniaci MJ, Ommen SR, Haddad TC. Development and implementation of a nurse-based remote patient monitoring program for ambulatory disease management. Front Digit Health. 2022; 4:1052408 Epub 2022 Dec 14
    View PubMed
  26. Pritchett JC, Haddad TC. Avoiding the "Faux Equalizer". Mayo Clin Proc. 2021 Dec; 96 (12):2963-2965 Epub 2021 Oct 30
    View PubMed
  27. Pritchett JC, Borah BJ, Desai AP, Xie Z, Saliba AN, Leventakos K, Coffey JD, Pearson KK, Speicher LL, Orenstein R, Virk A, Ganesh R, Paludo J, Halfdanarson TR, Haddad TC. Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. JCO Oncol Pract. 2021 Sep; 17 (9):e1293-e1302 Epub 2021 June 04
    View PubMed
  28. Coffey JD, Christopherson LA, Glasgow AE, Pearson KK, Brown JK, Gathje SR, Sangaralingham LR, Carmona Porquera EM, Virk A, Orenstein R, Speicher LL, Bierle DM, Ganesh R, Cox DL, Blegen RN, Haddad TC. Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19. NPJ Digit Med. 2021 Aug 13; 4 (1):123
    View PubMed
  29. Haddad TC, He J, O'Sullivan CC, Chen B, Northfelt D, Dueck AC, Ballman KV, Tenner KS, Linden H, Sparano JA, Hopkins JO, De Silva C, Perez EA, Haluska P, Goetz MP. Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). Breast Cancer Res Treat. 2021 Jul; 188 (2):477-487 Epub 2021 Apr 14
    View PubMed
  30. Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2021 Jun 15; 27 (12):3329-3338 Epub 2021 Apr 05
    View PubMed
  31. Jalalirad M, Haddad TC, Salisbury JL, Radisky D, Zhang M, Schroeder M, Tuma A, Leof E, Carter JM, Degnim AC, Boughey JC, Sarkaria J, Yu J, Wang L, Liu MC, Zammataro L, Malatino L, Galanis E, Ingle JN, Goetz MP, D'Assoro AB. Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance. Oncogene. 2021 Apr; 40 (14):2509-2523 Epub 2021 Mar 05
    View PubMed
  32. Haddad T, Helgeson JM, Pomerleau KE, Preininger AM, Roebuck MC, Dankwa-Mullan I, Jackson GP, Goetz MP. Accuracy of an Artificial Intelligence System for Cancer Clinical Trial Eligibility Screening: Retrospective Pilot Study. JMIR Med Inform. 2021 Mar 26; 9 (3):e27767
    View PubMed
  33. Ganesh R, Salonen BR, Bhuiyan MN, Bierle DM, Moehnke D, Haddad TC, Tande AJ, Wilson J, Hurt RT. Managing Patients in the COVID-19 Pandemic: A Virtual Multidisciplinary Approach. Mayo Clin Proc Innov Qual Outcomes. 2021 Feb; 5 (1):118-126 Epub 2020 Dec 15
    View PubMed
  34. Ingle JN, Kalari KR, Barman P, Shepherd LE, Ellis MJ, Goss PE, Buzdar AU, Robson ME, Cairns J, Carlson EE, Eyman Casey A, Hoskin TL, Goodnature BA, Haddad TC, Goetz MP, Weinshilboum RM, Wang L. Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenet Genomics. 2021 Jan; 31 (1):1-9
    View PubMed
  35. Haddad TC, Blegen RN, Prigge JE, Cox DL, Anthony GS, Leak MA, Channer DD, Underwood PY, Williams RD, Hofschulte RD, Christopherson LA, Coffey JD, TerKonda SP, Yiannias JA, Costello BA, Russi CS, Colby CE, Ommen SR, Demaerschalk BM. A Scalable Framework for Telehealth: The Mayo Clinic Center for Connected Care Response to the COVID-19 Pandemic. Telemed Rep. 2021; 2 (1):78-87 Epub 2021 Feb 24
    View PubMed
  36. Haque E, Alabdaljabar MS, Ruddy KJ, Haddad TC, Thompson CA, Lehman JS, Hashmi SK. Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions. Crit Rev Oncol Hematol. 2020 Dec; 156:103093. Epub 2020 Sep 22.
    View PubMed
  37. Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching PA, Hoskin TL, Singh RJ, Desta Z, Kalari KR, Ellis MJ, Goss PE, Chen BE, Volz B, Barman P, Carlson EE, Haddad T, Goetz MP, Goodnature B, Cuellar ME, Walters MA, Correia C, Kaufmann SH, Weinshilboum RM, Wang L. Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor alpha. Clin Cancer Res. 2020 Jun 15; 26 (12):2986-2996 Epub 2020 Feb 25
    View PubMed
  38. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 May 1; 6 (5):676-684
    View PubMed
  39. Lehmann BD, Abramson VG, Sanders M, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA, Translational Breast Cancer Research Consortium. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR(+) Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 May 1; 26 (9):2111-2123 Epub 2019 Dec 10
    View PubMed
  40. Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J, Gnanaolivu R, Lee KY, Lindstrom T, Armasu S, Fitz-Gibbon P, Ghosh K, Stan DL, Pruthi S, Neal L, Sandhu N, Rhodes DJ, Klassen C, Peethambaram PP, Haddad TC, Olson JE, Hoskin TL, Goetz MP, Domchek SM, Boughey JC, Ruddy KJ, Couch FJ. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. J Clin Oncol. 2020 May 1; 38 (13):1409-1418 Epub 2020 Mar 03
    View PubMed
  41. Ruddy KJ, Sangaralingham LR, Van Houten H, Nowsheen S, Sandhu N, Moslehi J, Neuman H, Jemal A, Haddad TC, Blaes AH, Villarraga HR, Thompson C, Shah ND, Herrmann J. Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy. Circ Cardiovasc Qual Outcomes. 2020 Mar; 13 (3):e005984 Epub 2020 Feb 28
    View PubMed
  42. Chaudhry AP, Pruthi S, Haddad TC, Liu H, Kessler ME, Ghosh K, Chaudhry R, Adusumalli J. Self-reported Need for Knowledge Management Solutions for DCIS Survivors amongst Primary Care Physicians. J Med Inform. 2020.
  43. Ruddy KJ, Herrin J, Sangaralingham L, Freedman RA, Jemal A, Haddad TC, Allen SV, Hieken T, Boughey JC, Ganz PA, Havyer RD, Shah ND. Follow-up Care for Breast Cancer Survivors. J Natl Cancer Inst 2020 Jan 1; 112 (1):111-113
    View PubMed
  44. Leventakos K, Helgeson J, Mansfield AS, Deering E, Schwecke A, Adjei A, Molina J, Hocum C, Halfdanarson T, Marks R, Parikh K, Pomerleau K, Coverdill S, Rammage M, Haddad T. Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center. Ann Oncol. 2019 Apr; 30 Suppl 2:ii74
    View PubMed
  45. Cheville AL, McLaughlin SA, Haddad TC, Lyons KD, Newman R, Ruddy KJ. Integrated Rehabilitation for Breast Cancer Survivors. Am J Phys Med Rehabil. 2019 Feb; 98 (2):154-164
    View PubMed
  46. Koehler LA, Haddad TC, Hunter DW, Tuttle TM. Axillary web syndrome following breast cancer surgery: symptoms, complications, and management strategies. Breast Cancer (Dove Med Press). 2019; 11:13-19 Epub 2018 Dec 20
    View PubMed
  47. Plummer R, Cook N, Arkenau T, Melear J, Redfern C, Spira AI, Chung K, Haddad T, Ramalingam SS, Wesolowski R, Dean E, Goddemeier T, Falk M, Shapiro G. Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2018 Oct; 29 Suppl 8:viii519
    View PubMed
  48. Leontovich AA, Jalalirad M, Salisbury JL, Mills L, Haddox C, Schroeder M, Tuma A, Guicciardi ME, Zammataro L, Gambino MW, Amato A, Di Leonardo A, McCubrey J, Lange CA, Liu M, Haddad T, Goetz M, Boughey J, Sarkaria J, Wang L, Ingle JN, Galanis E, D'Assoro AB. NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Res. 2018 Sep 4; 20 (1):105 Epub 2018 Sept 04
    View PubMed
  49. Leal AD, Van Houten H, Sangaralingham L, Freedman RA, Jemal A, Neuman HB, Haddad TC, Mutter RW, Keegan THM, Mougalian SS, Loprinzi CL, Gross CP, Shah N, Ruddy KJ. Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens. Clin Breast Cancer. 2018 Aug; 18 (4):e513-e520 Epub 2017 Sept 22
    View PubMed
  50. Koehler LA, Hunter DW, Blaes AH, Haddad TC. Function, Shoulder Motion, Pain, and Lymphedema in Breast Cancer With and Without Axillary Web Syndrome: An 18-Month Follow-Up. Phys Ther. 2018 Jun 1; 98 (6):518-527
    View PubMed
  51. O'Sullivan CC, Loprinzi CL, Haddad TC. Updates in the Evaluation and Management of Breast Cancer. Mayo Clin Proc. 2018 Jun; 93 (6):794-807
    View PubMed
  52. McRoy S, Rastegar-Mojarad M, Wang Y, Ruddy KJ, Haddad TC, Liu H. Assessing Unmet Information Needs of Breast Cancer Survivors: Exploratory Study of Online Health Forums Using Text Classification and Retrieval. JMIR Cancer. 2018 May 15; 4 (1):e10
    View PubMed
  53. Ruddy KJ, Sangaralingham L, Freedman RA, Mougalian S, Neuman H, Greenberg C, Jemal A, Duma N, Haddad TC, Lemaine V, Ghosh K, Hieken TJ, Hunt K, Vachon C, Gross C, Shah ND. Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors. J Natl Compr Canc Netw. 2018 May; 16 (5):526-534
    View PubMed
  54. Ohmine S, Salisbury JL, Ingle J, Pettinato G, Haddox CL, Haddad T, Galanis E, Ikeda Y, D'assoro AB. Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells. Oncol Rep. 2018 Apr; 39 (4):1725-1730 Epub 2018 Jan 31
    View PubMed
  55. Haddad TC, D'Assoro A, Suman V, Opyrchal M, Peethambaram P, Liu MC, Goetz MP, Ingle JN. Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast Cancer Res Treat. 2018 Apr; 168 (3):639-647 Epub 2017 Dec 30
    View PubMed
  56. Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ. Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Curr Treat Options Cardiovasc Med. 2018 Mar 1; 20 (2):18 Epub 2018 Mar 01
    View PubMed
  57. Gast KC, Allen SV, Ruddy KJ, Haddad TC. Novel approaches to support breast cancer survivorship care models. Breast. 2017 Dec; 36:1-13 Epub 2017 Aug 29
    View PubMed
  58. Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res. 2017 Nov 15; 23(22):6823-6832. Epub 2017 Sep 05.
    View PubMed
  59. Opyrchal M, Gil M, Salisbury JL, Goetz MP, Suman V, Degnim A, McCubrey J, Haddad T, Iankov I, Kurokawa CB, Shumacher N, Ingle JN, Galanis E, D'Assoro AB. Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. Oncotarget. 2017 Oct 31; 8 (53):91803-91816 Epub 2017 Sept 01
    View PubMed
  60. Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol. 2017 Oct 20; 35 (30):3391-3400 Epub 2017 Aug 30
    View PubMed
  61. Nowsheen S, Viscuse PV, O'Sullivan CC, Sandhu NP, Haddad TC, Blaes A, Klemp J, Nhola L, Herrmann J, Ruddy KJ. Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer. Curr Breast Cancer Rep. 2017 Sep; 9 (3):173-182 Epub 2017 July 14
    View PubMed
  62. Ruddy KJ, Van Houten HK, Sangaralingham LR, Freedman RA, Thompson CA, Hashmi SK, Jemal A, Haddad TC, Mougalian S, Herrin J, Gross C, Shah N. Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat. 2017 Aug; 164 (3):515-525 Epub 2017 May 10
    View PubMed
  63. Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017 Jun; 163 (3):535-544 Epub 2017 Mar 21
    View PubMed
  64. Haddad T, Qin R, Lupu R, Satele D, Eadens M, Goetz MP, Erlichman C, Molina J. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017 Jun; 79 (6):1221-1227 Epub 2017 May 05
    View PubMed
  65. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7; 375 (1):11-22
    View PubMed
  66. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 7; 375 (1):23-34
    View PubMed
  67. Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, McCullough AE, Winham SJ, Vachon CM, Ghosh K, Brandt KR, Farrell AM, Tarabishy Y, Hieken TJ, Haddad TC, Kraft RA, Radisky DC, Degnim AC. Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer. 2016 Feb 1; 122 (3):378-85 Epub 2015 Oct 29
    View PubMed
  68. Blaes AH, Fenner D, Bachanova V, Torkelson C, Geller M, Haddad T, Shanley R, Kreitzer MJ. Mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation Journal of Community and Supportive Oncology. 2016; 14: (8)351-8.
  69. Kasi PM, Hieken TJ, Haddad TC. Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer. Case Rep Oncol. 2016 Jan-Apr; 9 (1):33-8 Epub 2016 Jan 14
    View PubMed
  70. Koehler LA, Blaes AH, Haddad TC, Hunter DW, Hirsch AT, Ludewig PM. Movement, Function, Pain, and Postoperative Edema in Axillary Web Syndrome. Phys Ther. 2015 Oct; 95 (10):1345-53 Epub 2015 May 14
    View PubMed
  71. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 1; 21 (13):2911-5 Epub 2015 Feb 24
    View PubMed
  72. Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015 May; 22 (5):1408-15 Epub 2015 Mar 02
    View PubMed
  73. D'Assoro AB, Haddad T, Galanis E. Aurora-A Kinase as a Promising Therapeutic Target in Cancer. Front Oncol. 2015; 5:295 Epub 2016 Jan 06
    View PubMed
  74. Blaes A, Duprez D, Defor T, Shanley R, Beckwith H, Haddad T, Potter D, Yee D, Sanghavi K, Jacobson P. Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. Springerplus. 2015; 4:32 Epub 2015 Jan 23
    View PubMed
  75. Opyrchal M, Guruswamy Sangameswaran KD, Khoury T, Boland P, Galanis E, Haddad TC, D'Assoro AB. Aurora kinase inhibitors in breast cancer treatment American Journal of Hematology/Oncology. 2015; 11 (12):14-8
  76. Herrmann J, Herrmann SM, Haddad TC. New-onset heart failure in association with severe hypertension during trastuzumab therapy. Mayo Clin Proc. 2014 Dec; 89: (12)1734-9.
    View PubMed
  77. Koehler LA, Hunter DW, Haddad TC, Blaes AH, Hirsch AT, Ludewig PM. Characterizing axillary web syndrome: ultrasonographic efficacy. Lymphology. 2014 Dec; 47(4):156-63.
    View PubMed
  78. Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Lomberk GA, Haddad T, Degnim A, Lange C, Ingle JN, Galanis E, D'Assoro AB. Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERalpha expression in initially ERalpha+ breast cancer cells. PLoS One. 2014; 9 (5):e96995 Epub 2014 May 09
    View PubMed
  79. Scanlon M, Blaes A, Geller M, Majhail NS, Lindgren B, Haddad T. Patient Satisfaction with Physician Discussions of Treatment Impact on Fertility, Menopause and Sexual Health among Pre-menopausal Women with Cancer. J Cancer. 2012; 3:217-25. Epub 2012 May 16.
    View PubMed
  80. Jang S, Prizment A, Haddad T, Robien K, Lazovich D. Smoking and quality of life among female survivors of breast, colorectal and endometrial cancers in a prospective cohort study. J Cancer Surviv. 2011 Jun; 5(2):115-22. Epub 2010 Sep 02.
    View PubMed
  81. Blaes AH, Kreitzer MJ, Torkelson C, Haddad T. Nonpharmacologic complementary therapies in symptom management for breast cancer survivors. Semin Oncol. 2011 Jun; 38(3):394-402.
    View PubMed
  82. Bandhakavi S, Van Riper SK, Tawfik PN, Stone MD, Haddad T, Rhodus NL, Carlis JV, Griffin TJ. Hexapeptide libraries for enhanced protein PTM identification and relative abundance profiling in whole human saliva. J Proteome Res. 2011 Mar 4; 10(3):1052-61. Epub 2011 Jan 14.
    View PubMed
  83. Jang S, Chae YK, Haddad T, Majhail NS. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat. 2010 Jun; 121(2):273-9. Epub 2010 Mar 30.
    View PubMed
  84. Patnaik MM, Haddad T, Morton CT. Pregnancy and thrombophilia. Expert Rev Cardiovasc Ther. 2007 Jul; 5(4):753-65.
    View PubMed
  85. Haddad T, Yee D. Can genes predict the future? Minnesota Physician. 2007; 21:26.
  86. Haddad T, Yee D. Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncol. 2006 Feb; 2(1):101-10.
    View PubMed
  87. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006; 118(5):555-68. Epub 2006 Jan 04.
    View PubMed
  88. Lawrence JB, Bale LK, Haddad TC, Clarkson JT, Conover CA. Characterization and partial purification of the insulin-like growth factor (IGF)-dependent IGF binding protein-4-specific protease from human fibroblast conditioned media. Growth Horm IGF Res. 1999 Feb; 9(1):25-34.
    View PubMed
  89. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Erlichman C, Hartmann LC. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Clin Cancer Res. 1997 Oct; 3(10):1713-20.
    View PubMed
  90. Haddad TC, Conover CA. Insulin and interleukin-4 induce desensitization to the mitogenic effects of insulin-like growth factor-I. Pivotal role for insulin receptor substrate-2. J Biol Chem. 1997 Aug 1; 272 (31):19525-31
    View PubMed
PST-20226684